• LAST PRICE
    7.0500
  • TODAY'S CHANGE (%)
    Trending Up0.0100 (0.1420%)
  • Bid / Lots
    6.6000/ 10
  • Ask / Lots
    7.6000/ 5
  • Open / Previous Close
    7.0400 / 7.0400
  • Day Range
    Low 6.8000
    High 7.1500
  • 52 Week Range
    Low 2.4400
    High 8.8400
  • Volume
    99,857
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Mar 14, 2024

      Show headlines and story abstract
    • 2:11PM ET on Thursday Mar 14, 2024 by MT Newswires
      Companies Mentioned: GLUE
      02:11 PM EDT, 03/14/2024 (MT Newswires) -- Monte Rosa Therapeutics (GLUE) reported Q4 net loss Thursday of $0.58 per diluted share, narrowing from the loss of $0.63 a year earlier. Analysts polled by Capital IQ expected a loss of $0.39. Cash and cas...
    • 7:00AM ET on Thursday Mar 14, 2024 by GlobeNewswire
      Companies Mentioned: GLUE
    • 7:00AM ET on Thursday Mar 14, 2024 by Dow Jones
      Companies Mentioned: GLUE
      Other receivables 505 7,656 Prepaid expenses and other current assets 3,294 4,444 Current restricted cash -- 960 -------- ----------- Total current assets 236,212 275,886 Property and equipment, net 33,803 27,075 Operating lease right-of-use assets 28,808 34,832 Restricted cash, net of current 4,580 4,318 Other long-term assets 352 278 -------- ----------- Total assets $ 303,755 $ 342,389 -------- ----------- Liabilities and stockholders' equity Current liabilities: Accounts payable $ 11,152 $ 7,862 Accrued expenses and other current liabilities 14,600 14,580 Current deferred revenue 17,678 -- Current portion of operating lease liability 3,162 3,127 -------- ----------- Total current liabilities 46,592 25,569 Deferred revenue, net of current 32,323 -- Defined benefit plan liability 2,713 1,533 Operating lease liability 42,877 43,874 -------- ----------- Total liabilities 124,505 70,976 -------- ----------- Commitments and contingencies Stockholders' equity Common stock, $0.0001 par value; 500,000,000 shares authorized, 50,154,929 shares issued and 50,140,233 shares outstanding as of December 31, 2023; and 500,000,000 shares authorized, 49,445,802 shares issued and 49,323,531 shares outstanding as of December 31, 2022 5 5 Additional paid-in capital 547,857 503,696 Accumulated other comprehensive loss (2,724) (1,752 ) Accumulated deficit (365,888) (230,536 ) -------- ----------- Total stockholders' equity 179,250 271,413 -------- ----------- Total liabilities and stockholders' equity $ 303,755 $ 342,389 ------------------------ -------- ----------- Consolidated Statements of Operations and Comprehensive Income (Loss) (In thousands, except share and per share amounts) Three months ended Year ended December 31, December 31, ------------------------- ------------------------- 2023 2022 2023 2022 ---------------------- ----------- ----------- ----------- ----------- Operating expenses: Research and development $ 27,135 $ 24,868 $ 111,272 $ 85,061 General and administrative 7,728 7,621 32,039 27,323 ---------- ---------- ---------- ---------- Total operating expenses 34,863 32,489 143,311 112,384 ---------- ---------- ---------- ---------- Loss from operations (34,863) (32,489) (143,311) (112,384) Other income (expense): Interest income, net 2,368 1,990 9,334 3,764 Foreign currency exchange gain (loss), net (779) (283) (930) 10 Gain on disposal of fixed assets -- -- 24 109 Loss on sale of marketable securities -- -- (131) -- ---------- ---------- ---------- ---------- Total other income 1,589 1,707 8,297 3,883 ---------- ---------- ---------- ---------- Net loss before income taxes $ (33,274) $ (30,782) $ (135,014) $ (108,501) Provision for income taxes 22 -- (338) -- ---------- ---------- ---------- ---------- Net loss $ (33,252) $ (30,782) $ (135,352) $ (108,501) ---------- ---------- ---------- ---------- Net loss per share attributable to common stockholders--basic and diluted $ (0.58) $ (0.63) $ (2.63) $ (2.30) ---------- ---------- ---------- ---------- Weighted-average number of shares outstanding used in computing net loss per common share--basic and diluted 56,927,647 48,893,160 51,396,961 47,227,370 ---------- ---------- ---------- ---------- Comprehensive loss: Net loss $ (33,252) $ (30,782) $ (135,352) $ (108,501) Provision for pension benefit obligation (1,411) 619 (1,369) 718 Unrealized gain (loss) on available-for-sale securities 142 231 397 (449) ---------- ---------- ---------- ---------- Comprehensive loss $ (34,521) $ (29,932) $ (136,324) $ (108,232) ----------------------- ---------- ---------- ---------- ----------
    • 7:00AM ET on Thursday Mar 14, 2024 by Dow Jones
      Companies Mentioned: GLUE
  • Mar 11, 2024

Peers Headlines